%0 Journal Article %T Efficacy and safety of apatinib in patients with metastatic colorectal cancer refractory to standard therapies %A Lv, Wangxia %A Yuan, Meiqin %A Zhao, Yazheng %A Shi, Zhong %A Yang, Yunshan %A Zhong, Haijun %J Translational Cancer Research %D 2018 %B 2018 %9 %! Efficacy and safety of apatinib in patients with metastatic colorectal cancer refractory to standard therapies %K %X Background: To evaluate the efficacy and safety of apatinib in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies. Methods: Patients with refractory mCRC received 500 mg of apatinib once a day in a 28-day cycle. Response was assessed using the RECIST 1.1 criteria, and toxicity was graded using CTCAE version 4.03. Survival analysis was performed by Kaplan-Meier method. Results: Forty-one patients were included in the present study. Among these patients, 4 patients achieved partial response and 27 achieved stable disease. The response rate was 9.8%, and disease control rate was 75.6%. Median progression-free survival and overall survival were 2.9 months (95% CI: 2.4–3.5) and 8.9 months (95% CI: 8.0–9.8), respectively. The grade 3/4 toxicities observed in this study were hand-foot syndrome (HFS, 6/41, 14.6%), hypertension (5/41, 12.2%) and leukopenia (5/41, 12.2%). Conclusions: Apatinib appears to be effective for the treatment of refractory mCRC with a manageable tolerability profile. %U https://tcr.amegroups.org/article/view/20611 %V 7 %N 2 %P 420-427 %@ 2219-6803